NEW JERSEY ALLIANCE FOR
CLINICAL AND TRANSLATIONAL SCIENCE
NEWS, EVENTS, and DEADLINES
|
|
Upcoming NJ ACTS and Rutgers Events
|
|
Data Science Workshop Series
Interested in learning data science and modern computational tools for your research? Join the Office of Advanced Research Computing (OARC) Data Science Workshop Series. Registration is now open for the next Machine Learning with Python and Scikit-Learn workshop to be held on March 11 at 2:00 p.m. In this three-hour workshop, you can learn the basics of unsupervised and supervised methods, discuss some of the popular models such as Support Vector Machines, Decision Trees, and Random Forest, and show how these models work for classification and regression problems. If you have questions or need assistance, contact Bala Desinghu.
March 11, 2022
2pm
|
|
NJ ACTS BERD Core Spring Workshop Series
Causal Mediation Analysis
|
|
Jason Roy, PhD
Chair, Department of Biostatistics and Epidemiology
RUBIES Director
March 17, 2022
3 - 4 pm
|
|
Rutgers Biomedical Health Sciences Faculty Affairs
Peer Mentor Meet & Greet
Join M. Maral Mouradian, MD, Vice Chancellor for Faculty Development for an online faculty gathering.
During this event, you will have the opportunity to:
- Meet the Vice Chancellor for Faculty Development to discuss mentoring at RBHS Network with faculty peers and exchange ideas about growth and development
- Ask questions about the mentoring program at RBHS.
All interested faculty are invited to attend.
April 5, 2022
12 pm - 1 pm
|
|
Road to Commercialization Symposium Series:
R U Protecting Your Innovative Idea?
Join the Innovation Ventures’ Road to Commercialization Symposium Series and learn how to protect your innovative idea!
Hear from prolific faculty researchers about how they developed their technologies, engaged with Innovation Ventures, secured commercialization focused funding, and attracted industry interest to advance the commercialization of their innovative ideas.
April 7, 2022
9:30 am - 12:30 pm
Please note: Attendance is required for researchers seeking TechAdvance® and HealthAdvance® funding.
|
|
NJ ACTS Services: Informatics Core
|
|
Informatics Services integrates, enhances and expands data from disparate clinical and research sources for researchers as well as augments analytics capabilities and training across the research enterprise.
Available Services
|
|
Princeton Spin-off Announces Seed Funding
|
|
NJ ACTS congratulates Zemer Gitai, PhD, the Edwin Grant Conklin Professor of Biology and professor of molecular biology at Princeton University, and founder of ArrePath, a drug discovery spin-off. ArrePath has received a seed round of $20 million to advance its proprietary, machine learning-based platform for discovering new classes of anti-infectives. The startup company addressing the growing challenge of antibacterial resistance, identifying new antibiotics that more effectively treat drug-resistant infections. Dr. Gitai has served as a member of the NJ ACTS Pilot Project Management Committee and a mentor for a NJ ACTS trainee. He has also received a pilot award from NJ ACTS for other work in his research group.
|
|
Rutgers Leadership in the National Institutes of Health
Researching COVID to Enhance Recovery (RECOVER)
The NIH RECOVER Program is a $470 million initiative to learn why some people develop “Long COVID”, and how they can recover from prolonged, new, or returning symptoms after the initial acute phase of infection.by the NIH. “Long COVID” is also known as post-acute sequelae of COVID-19 (PASC). The RECOVER initiative, which will involve approximately 40,000 adult and pediatric participants across the United States and abroad, launched in 2021 and will continue for four years.
NJ ACTS is especially proud of the leadership of Dr. Lawrence Kleinman and Dr. Maria Gennaro in the RECOVER Program. Congratulations to both of you.
Maria Gennaro to Lead Microbiology Committee for NIH-RECOVER
|
|
Maria Gennaro, MD, MSc, Professor in the Department of Medicine in NJMS and Professor of Epidemiology in the School of Public Health, has been nominated Inaugural Chair of the Microbiology Committee of the National Institutes of Health (NIH) Researching COVID to Enhance Recovery ( RECOVER) program. The Microbiology Committee is one of six Pathobiology Multi-Disciplinary Task Force Committees coordinated by the RECOVER Clinical Science Core. Its goal is to shape the RECOVER protocols in important ways and to be a conduit between RECOVER investigators and Rutgers microbiologists who work on problems relevant to the study of Long COVID. Dr. Gennaro directs the NJ ACTS Biomarkers Core, with expertise in immunology, molecular and cellular biology; since the beginning of the COVID-19 public health crisis, Dr. Gennaro and her team have supported COVID-19 research and non-oncological translational research.
Lawrence Kleinman to Lead Enrollment Hub for Pediatric RECOVER Study
|
|
Lawrence Kleinman, a professor and vice chair of the Department of Pediatrics at RWJMS and a professor of global public health at the Rutgers School of Public Health and lead investigator for the Collaborative Long-term Study of Outcomes of COVID-19 in Kids (CLOCK) consortium at Rutgers. The CLOCK team will recruit children, adolescents and young adults from across the United States into the NIH’s RECOVER cohort study. RWJMS is expected to receive $30 million as part of its partnership with the RECOVER program to study long-term and delayed impacts of COVID-19 in children.
|
|
NJ ACTS Job Opening - Princeton
|
|
NJ ACTS Grants Manager
Princeton University is seeking to fill a remote, part-time, 2-year term position for a Grants Manager who will be the primary grants manager at Princeton for the New Jersey Alliance for Clinical and Translation Science (NJ ACTS) award. Submission of a resume and a cover letter is required.
|
|
Upcoming CTSA and Other Events
|
|
Registration now open for 2022 CTSA Program
In-Person Spring Group Meetings
This Chicago, IL event is first in-person spring CTSA Program Group Meetings in over two years!
Friday, April 22 & Saturday, April 23, 2022
Registration Deadline: Friday, April 1, 2022
|
|
The NCATS/NIH Genomics Information Commons Un-Meeting on
Enabling and Promoting Inter-Institutional Clinical and Genomic Research
April 13, 2022
The Genomics Information Commons (GIC) invites the community to a NCATS-sponsored Un-Meeting on “Enabling and Promoting Inter-Institutional Clinical and Genomic Research.” The goal of the meeting is to solicit innovative and collaborative ideas from across the CTSA Consortium to evaluate acceptability and scalability of the GIC’s prototype system, and to ideate around next steps and future directions. Specific topics include: using and analyzing federated genome and phenome data; aligning consenting processes across the Consortium; GIC research topic opportunities – low hanging fruit; facilitation of inter-institutional research collaboration; and GIC cloud-hosted data and analytic environments and technologies for local institutional research.
The Genomic Information Commons (GIC) is an NCATS/NIH funded continuously updating, queryable, federated system enabling and promoting clinical and genomic research across eight pediatric hospitals. The GIC has established highly scalable technologies, policies, and procedures for sharing genomic data, phenotypic data, and biospecimen metadata on broadly consented cohorts, across sites of care.
|
|
2022 Regeneron Science to Medicine Forum
A regional biomedical conference to encourage cross-fertilization and interaction between graduate students and postdoctoral fellows doing great science across the New York Metro Area.
As in prior years, we are inviting your students and trainees to submit abstracts for consideration, with high merit abstracts receiving invitations to present during the Forum.
In addition to scientific talks from participants, there will also be an opportunity to gather information about Regeneron’s postdoctoral training program and other career opportunities at Regeneron.
June 16, 2022
9 am - 5 pm
|
|
Online Course
Introduction to the Multiphase Optimization Strategy (MOST)
This course is aimed at intervention scientists working in any area--including public health, education, criminal justice, and others—interested in learning about an innovative framework for conducting intervention research. This course will show you how to use the multiphase optimization strategy (MOST) to: streamline interventions by eliminating inactive components; identify the combination of components that offers the greatest effectiveness without exceeding a defined implementation budget; develop interventions for immediate scalability; look inside the “black box” to understand which intervention components work and which do not; and improve interventions programmatically over time.
|
|
Master’s of Science in Clinical Research Management. Academic Clinical Research Track. This track is especially designed for students with no clinical research or pharmaceutical experience who would like to participate in clinical research at an Academic Medical Center (AMC) functioning as a “study coordinator”. Application Deadline Extended to May 1, 2022.
|
|
Regulatory Knowledge and Support Core Staff Cafés - Do you need help regarding any facet of human subjects protection, FDA requirements or other regulatory issues? Join the Regulatory Knowledge and Support Core Staff at our cafés. Next Cafe is March 24, 2022,
|
|
On the Pandemic Podcast - Episode 6: Kids and Covid: What We Know, Lawrence C. Kleinman, Rutgers Robert Wood Johnson Medical School.
|
|
NJ ACTS is a partnership between Rutgers, NJIT and Princeton. NJ ACTS advances clinical and translational science to develop new therapies and treatments and improve population health.
|
|
This newsletter is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number, UL1TR003017 to Rutgers University. The content is solely the responsibility of the authors and does not represent the official views of the NIH.
New Jersey Alliance for Clinical and Translational Science
89 French St., Suite 4211
New Brunswick, NJ
Copyright 2020 New Jersey Alliance for Clinical and Translational Science, all rights reserved
UL1TR003017, KL2TR003018 and TL1TR003019
|
|
|
|
|
|
|
|
|